Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Better Bonding Between U.S., Indian Regulators Can Ensure Good Quality Of Data From India's Clinical Trial Sites, Say Experts

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Select Indian clinical research organizations have called for greater collaboration between drug regulators in India and the U.S. to increase confidence about the quality and reliability of clinical trial data being increasingly generated at scores of Indian sites

You may also be interested in...



Patient Safety First: Indian Regulator Takes Steps To Tighten Grip Over Site Inspections, Ensure Data Credibility

MUMBAI - As India moves rapidly to become an integral part of large-scale global clinical trials, the Central Drugs Standard Control Organization under the Ministry of Health and Family Welfare has declared a set of new guidelines to ensure adequate safety of trial participants

Patient Safety First: Indian Regulator Takes Steps To Tighten Grip Over Site Inspections, Ensure Data Credibility

MUMBAI - As India moves rapidly to become an integral part of large-scale global clinical trials, the Central Drugs Standard Control Organization under the Ministry of Health and Family Welfare has declared a set of new guidelines to ensure adequate safety of trial participants

Data Integrity A Key Concern In Foreign Trials

As more and more clinical trials are done outside the U.S., sponsors must be careful to ensure that sites are in compliance with FDA data integrity rules as well as ethical criteria, Barbara Gotthelf, a partner at McCarter & English, said in a Sept. 22 webinar sponsored by Medmarc.

UsernamePublicRestriction

Register

LL038093

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel